Brogden R N, Wiseman L R
Drugs. 1996 Jul;52(1):113-24. doi: 10.2165/00003495-199652010-00008.
Aceclofenac is a phenylacetic acid derivative with anti-inflammatory and analgesic properties similar to those of diclofenac. However, preclinical studies suggest that the potential of aceclofenac to cause gastrointestinal damage is less than that of diclofenac. Double-blind comparative trials indicate that the efficacy of aceclofenac is at least equivalent to that of ketoprofen and similar to that of indomethacin and diclofenac in patients with rheumatoid arthritis, similar to that of diclofenac and piroxicam in patients with osteoarthritis of the knee and similar to that of tenoxicam, indomethacin and naproxen in patients with ankylosing spondylitis. The analgesic efficacy of aceclofenac 100mg is more prolonged than that of paracetamol (acetaminophen) 650mg. If the apparently improved gastrointestinal tolerability of aceclofenac compared with diclofenac is confirmed by wider clinical experience, aceclofenac will have the potential to become a preferred initial drug in an individualised NSAID regimen in patients with rheumatic disorders.
醋氯芬酸是一种苯乙酸衍生物，具有与双氯芬酸相似的抗炎和镇痛特性。然而，临床前研究表明，醋氯芬酸导致胃肠道损伤的可能性低于双氯芬酸。双盲对比试验表明，在类风湿性关节炎患者中，醋氯芬酸的疗效至少与酮洛芬相当，与吲哚美辛和双氯芬酸相似；在膝关节骨关节炎患者中，与双氯芬酸和吡罗昔康相似；在强直性脊柱炎患者中，与替诺昔康、吲哚美辛和萘普生相似。100毫克醋氯芬酸的镇痛效果比650毫克对乙酰氨基酚（扑热息痛）更持久。如果与双氯芬酸相比，醋氯芬酸明显改善的胃肠道耐受性能被更广泛的临床经验所证实，那么醋氯芬酸将有可能成为风湿性疾病患者个体化非甾体抗炎药治疗方案中的首选初始药物。
